- Home
- ANAB vs XPEL Comparison
ANAB vs XPEL Comparison
Compare ANAB & XPEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- XPEL
- Stock Information
- Founded
- ANAB 2005
- XPEL 1999
- Country
- ANAB United States
- XPEL United States
- Employees
- ANAB N/A
- XPEL N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- XPEL Industrial Specialties
- Sector
- ANAB Health Care
- XPEL Industrials
- Exchange
- ANAB Nasdaq
- XPEL Nasdaq
- Market Cap
- ANAB 1.0B
- XPEL 984.3M
- IPO Year
- ANAB 2017
- XPEL N/A
- Fundamental
- Price
- ANAB $38.47
- XPEL $36.14
- Analyst Decision
- ANAB Buy
- XPEL
- Analyst Count
- ANAB 12
- XPEL 0
- Target Price
- ANAB $63.30
- XPEL N/A
- AVG Volume (30 Days)
- ANAB 364.4K
- XPEL 258.5K
- Earning Date
- ANAB 11-04-2025
- XPEL 11-05-2025
- Dividend Yield
- ANAB N/A
- XPEL N/A
- EPS Growth
- ANAB N/A
- XPEL N/A
- EPS
- ANAB N/A
- XPEL 1.69
- Revenue
- ANAB $169,467,000.00
- XPEL $461,460,000.00
- Revenue This Year
- ANAB $37.52
- XPEL $12.54
- Revenue Next Year
- ANAB N/A
- XPEL $10.52
- P/E Ratio
- ANAB N/A
- XPEL $21.41
- Revenue Growth
- ANAB 196.42
- XPEL 10.29
- 52 Week Low
- ANAB $12.21
- XPEL $24.25
- 52 Week High
- ANAB $40.96
- XPEL $47.23
- Technical
- Relative Strength Index (RSI)
- ANAB 72.78
- XPEL 58.50
- Support Level
- ANAB $34.22
- XPEL $31.88
- Resistance Level
- ANAB $37.08
- XPEL $37.11
- Average True Range (ATR)
- ANAB 2.03
- XPEL 1.55
- MACD
- ANAB -0.18
- XPEL 0.03
- Stochastic Oscillator
- ANAB 68.07
- XPEL 74.53
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.